Patent map
Who can copy which drug, and where
Patent protection for semaglutide, tirzepatide and orforglipron, country by country. Semaglutide lost protection in India, China, Brazil and Canada in 2026; the US, Europe and Japan stay protected into the 2030s.
World map
Semaglutide injection (Ozempic, Wegovy)
Hover a country for its status, the date and the source.
Patent expired March 2026. Anvisa approved EMS's generic pen in May 2026.
Peptide News Digest: GLP-1 patent expiration timeline (Oct 2026)Main patent lapsed after an unpaid fee; data protection ended January 2026. Apotex and Dr. Reddy's launched May 14, 2026.
The Rx Index: GLP-1 US patent and exclusivity database (Sept 2026)Core patent expired March 20, 2026. 12 copies from 10 companies were awaiting approval in early October 2026.
Peptide News Digest: GLP-1 patent expiration timeline (Oct 2026)Core patent expired March 20, 2026. Generics on sale from March 21 (Dr. Reddy's, Zydus, Sun Pharma, Alkem, Glenmark).
Peptide News Digest: GLP-1 patent expiration timeline (Oct 2026)Compound patent with supplementary protection to 2031. Secondary patents are being challenged, including by Sandoz at the Unified Patent Court.
Reddie & Grose: changes in the Ozempic patent landscape (Feb 2026)Compound patent to 2031.
Selborne Research: pharma patent expiry by company (from FY2025 filings)Compound patent to December 2031 (Novo lists 2032); later patents run to 2041. Settlement dates with generic makers are confidential.
The Rx Index: GLP-1 US patent and exclusivity database (Sept 2026)Timeline
When protection ends, by market
Compound patents unless noted. The dashed line is today.
Semaglutide injection Ozempic, Wegovy
Semaglutide pill Rybelsus, Wegovy pill
Tirzepatide Mounjaro, Zepbound
Orforglipron Foundayo
How to read this map
The colour shows when the compound patent, the one that covers the molecule itself, expires, including extensions such as supplementary protection certificates in Europe. A copy can still be blocked by later patents on formulations, doses, devices or uses, and by regulatory data protection, as happened in Canada until January 2026.
Patent expiry is also not the same as a launch. A generic needs regulatory approval, which took weeks in India and is still pending in China. In the US, settlements between Novo Nordisk and generic makers have confidential entry dates, so the first US generics could come before or after 2032.
Grey means we have no reliable public data for that drug in that country, not that the drug is unprotected there. Europe is shown as one block; supplementary protection can differ slightly by country.
Sources
- Peptide News Digest: GLP-1 patent expiration timeline (Oct 2026)
- The Rx Index: GLP-1 US patent and exclusivity database (Sept 2026)
- Reddie & Grose: changes in the Ozempic patent landscape (Feb 2026)
- Novo Nordisk Form 20-F, FY2025
- Selborne Research: pharma patent expiry by company (from FY2025 filings)
- GreyB Pharsight: tirzepatide US patents
- GreyB Pharsight: Foundayo US patents and exclusivity